The Drug-Dosing Conundrum in Oncology — When Less Is More-Reference-Cited by-同舟云学术

The Drug-Dosing Conundrum in Oncology — When Less Is More

Published:2021-10-14 Issue:16 Volume:385 Page:1445-1447
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Shah Mirat¹,Rahman Atiqur¹,Theoret Marc R.¹,Pazdur Richard¹

Affiliation:

1. From the Office of Oncologic Diseases (M.S.) and the Division of Cancer Pharmacology II, Office of Clinical Pharmacology (A.R.), Center for Drug Evaluation and Research, and the Oncology Center of Excellence (M.R.T., R.P.), Food and Drug Administration, Silver Spring, MD.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMp2109826

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bayesian pharmacokinetics integrated phase I–II design to optimize dose-schedule regimes;Biostatistics;2024-09-13

2. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

3. Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs;Journal of Clinical Oncology;2024-09-03

4. Bayesian Predictive Probability Based on a Bivariate Index Vector for Single‐Arm Phase II Study With Binary Efficacy and Safety Endpoints;Pharmaceutical Statistics;2024-08-13

5. Strategies for successful dose optimization in oncology drug development: a practical guide;Journal of Biopharmaceutical Statistics;2024-08-11